Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21242477 | 0.80 | NOS1 (0.55) | ALDH1A1KDM4EHSD17B10EPHX2NPC1 | |
| SCHEMBL19721706 | 0.79 | KDM4E (0.46) | ALDH1A1KDM4EHSD17B10EPHX2MEN1 | |
| SCHEMBL3072249 | 0.78 | KDM4E (0.48) | ALDH1A1KDM4EHSD17B10EPHX2MEN1 | |
| SCHEMBL869424 | 0.75 | KDM4E (0.50) | ALDH1A1KDM4EHSD17B10EPHX2MEN1 | |
| SCHEMBL27671493 | 0.73 | SMN1; SMN2 (0.46) | ALDH1A1KDM4EHSD17B10EPHX2MEN1 | |
| SCHEMBL2246884 | 0.73 | DPP4 (0.47) | ALDH1A1KDM4EHSD17B10EPHX2MEN1 | |
| SCHEMBL5757978 | 0.73 | DPP4 (0.51) | ALDH1A1KDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL16291133 | 0.72 | L3MBTL1 (0.57) | ALDH1A1KDM4EHSD17B10EPHX2MEN1 | |
| SCHEMBL3545 | 0.72 | L3MBTL1 (0.57) | ALDH1A1KDM4EHSD17B10EPHX2MEN1 | |
| SCHEMBL2645238 | 0.72 | NPC1 (0.53) | ALDH1A1KDM4EHSD17B10EPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078902-B2 | Triazine derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-02 | — | — | US | disclosed |
| CN-102573480-A | Triazine derivatives and their therapeutic use | ABRAXIS BIOSCIENCE LLC | 2012-07-11 | — | — | CN | disclosed |
| EP-2440057-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | Abraxis BioScience, LLC (US) | 2012-04-18 | — | — | EP | disclosed |
| US-7868030-B2 | FBPase inhibitors for diabetes | HOFFMANN-LA ROCHE INC. (US) | 2011-01-11 | — | — | US | disclosed |
| WO-2010144550-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| EP-2032548-A1 | THIAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007137962-A1 | THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281979-A1 | Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents | HOFFMANN-LA ROCHE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281979-A1 | Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents | FBP1, PFKFB1, PFKFB3 | ALDH1A1 565/4885KDM4E 1403/4885HSD17B10 1696/4885 |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | MAP3K2, MAP3K5, MAP4K2 | ALDH1A1 3921/4885KDM4E 2636/4885HSD17B10 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.